Table 1 Incidence and prevalence of isolated candida species among different patient categories using VITEK2 YST® platform
Category of patients | Candida isolates in blood culture from VITEK2 YST® platform | Number of cases | Period prevalence (%) | Incidence/100,000-person years | Comments and p value |
|---|---|---|---|---|---|
Overall | C. albicans | 34 | 1.7 X 10 −4% | 0.113 | 0.03 non- albicans period prevalence and incidence was significantly higher than candidemia following albicans |
Non- albicans | 76 | 4.1 X 10 −4% | 0.23 | ||
C. parapsilosis | 22 | 1.1 X 10 −4% | 0.07 | ||
C. tropicalis | 18 | 1.0 X 10 −4% | 0.06 | ||
C. krusei | 12 | 8 X 10 −5% | 0.04 | ||
C. glabrata | 12 | 8 X 10 − 5% | 0.04 | ||
C. haemulonii | 6 | 4 X 10 −5% | 0.02 | ||
Other | 6 | 4 X 10 −5% | 0.02 | ||
Neonates in intensive care units | C. albicans | 2 | 2 X 10 −3% | 0.133 | 0.02 non- albicans period prevalence and incidence was significantly higher than candidemia following albicans |
Non- albicans | 8 | 9 X 10−3% | 0.6 | ||
C. parapsilosis | 1 | 2 X 10 −3% | 0.133 | ||
C. tropicalis | 3 | 3 X 10 −3% | 0.2 | ||
C. krusei | 1 | 2 X 10 −3% | 0.133 | ||
C. glabrata | 2 | 2 X 10 −3% | 0.133- | ||
C. haemulonii | 0 | ||||
Infants in intensive care units | C. albicans | 6 | 3 X 10–3% | 0.2 | 0.04 non- albicans period prevalence and incidence was significantly higher than candidemia following albicans |
Non- albicans | 7 | 6 X 10–3% | 0.4 | ||
C. parapsilosis | 1 | 2 X 10–3% | 0.133 | ||
C. tropicalis | 3 | 1.5 X 10–3% | 0.1 | ||
C. glabrata | 2 | 1.5 X 10–3% | 0.066 | ||
C. krusei | 1 | 1 X 10–3% | 0.066 | ||
C. haemulonii | 0 | ||||
Adults in intensive care units | C. albicans | 22 | 1.8 X 10–4% | 0.12 | 0.02 non- albicans period prevalence and incidence was significantly higher than candidemia following albicans |
Non- albicans | 56 | 3.8 X 10–4% | 0.25 | ||
C. parapsilosis | 20 | 1.4 X 10–4% | 0.09 | ||
C. tropicalis | 12 | 9 X 10–5% | 0.06 | ||
C. glabrata | 9 | 6 X 10–5% | 0.04 | ||
C. krusei | 9 | 6 X 10–5% | 0.04 | ||
C. haemulonii | 6 | 3 X 10–5% | 0.02 | ||
Immunocompromised patients (having neutropeniaa) | C. albicans | 22 | 1.1 X 10–3% | 1.13 | 0.03 non- albicans period prevalence and incidence was significantly higher than candidemia following albicans |
Non- albicans | 51 | 3.4 X 10–3% | 1.68 | ||
C. tropicalis | 16 | 8 X 10–4% | 0.53 | ||
C. parapsilosis | 10 | 5 X 10–4% | 0.33 | ||
C. glabrata | 10 | 5 X 10–4% | 0.33 | ||
C. krusei | 10 | 5 X 10–4% | 0.33 | ||
C. haemulonii | 5 | 1.1 X 10–5% | 0.16 |